Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
RenBio logo — DNA Therapeutics: Delivering Next-Generation Medicines

RenBio

DNA Therapeutics: Delivering Next-Generation Medicines

Founded 2016 United States United States 8 employees Series A Total: $43.86M Biotechnology

General Information

Company Name RenBio
Founded Year 2016
Location United States United States
Employees 8
Industries Biotechnology
Funding Stage Series A
Business Model B2G, B2B, Platform
Revenue Model Licensing, Product Sales, Value Based Pricing
Social

BounceWatch is an independent company data service, not affiliated with RenBio. To contact RenBio, visit renbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does RenBio compare?

A PDF of RenBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting RenBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About RenBio

RenBio, a pioneering player in the Biotechnology industry, is focused on making the transformative benefits of antibody therapeutics universally accessible. Founded in 2016 by distinguished scientists David D. Ho, MD and Yaoxing Huang, PhD, it swiftly gained industry recognition, being named one of DARPA’s “Biotech Startups of the Future” within a year of operation. The founders' affiliations with the Aaron Diamond AIDS Research Center and Columbia University Medical Center underscore the company's strong scientific foundation.

The New York City-based company enjoys substantial backing from renowned entities such as the Bill & Melinda Gates Foundation, DARPA, BARDA, Wellcome Trust, and a coalition of private investors. As of July 2024, RenBio secured a $2.90M grant investment, further reinforcing its financial stability to innovate in DNA Therapeutics.

Business keywords: Antibody Therapeutics, Antibody Engineering, Antibody Delivery, Next-Generation Medicines, Medical Innovation, Biotech Startups, Therapeutic Development, Healthcare Innovation, Biopharmaceuticals, Medical Research, Pharmaceutical R&D

Services & Products

Development of DNA-based therapeutic technologies
Production and delivery of antiviral antibodies
Improvement of dosing regimens and effectiveness of therapeutic proteins
Research and innovation in antibody and protein therapeutics

Target Customers

Healthcare Providers Pharmaceutical Companies Medical Researchers Patients with infectious diseases Organizations focused on disease prevention

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $2.90M -
01 Jul 2024
Grant $2.00M 1
DARPA
DARPA
01 Oct 2022
Series A $24.00M 1
The Group Ventures
The Group Ventures
01 May 2021
Early VC $14.00M -
01 Jan 2021
Grant $960.00K 1
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
01 Aug 2019
Spinout Undisclosed 1
Columbia University
01 Jan 2016

RenBio Alternatives & Competitors

View All Alternatives
RenBio vs
ImmunAbs Inc.
ImmunAbs Inc.

ImmunAbs Inc. is Specialized Antibody Pharmaceutical Development Biotech Venture. "Hope for Patient...

Series B
11 employees
Biotechnology, Health Care
RenBio vs
Genmab
Genmab Denmark

Differentiated human antibody therapeutics for the treatment of cancer

IPO
2981 employees
Biotechnology, Pharmaceutical
RenBio vs
Protillion Biosciences
Protillion Biosciences United States

Revolutionary deep tech for the design and development of protein-based drugs

Series A
23 employees
Biopharma, Biotechnology
View all alternatives

FAQ About RenBio

DNA Therapeutics: Delivering Next-Generation Medicines
RenBio was founded in 2016.
RenBio is headquartered in United States.
RenBio operates in Biotechnology. Its work centres on Antibody Therapeutics, Antibody Engineering, Antibody Delivery and Next-Generation Medicines. Its customers include Healthcare Providers, Pharmaceutical Companies and Medical Researchers.
RenBio has a B2G, B2B and Platform business model. Its revenue comes from Licensing, Product Sales and Value Based Pricing.
RenBio has approximately 8 employees.
RenBio has completed 6 funding rounds, raising a total of $43.86M. The latest funding stage is Series A.
RenBio offers: Development of DNA-based therapeutic technologies, Production and delivery of antiviral antibodies, Improvement of dosing regimens and effectiveness of therapeutic proteins, Research and innovation in antibody and protein therapeutics.
Top alternatives and competitors to RenBio include ImmunAbs Inc., Genmab, Protillion Biosciences, BigHat Biosciences, Stylus Medicine. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RenBio and ImmunAbs Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for RenBio, https://bouncewatch.com/company/renbio, updated 4 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes